Author(s): Swain SM, Whaley FS, Ewer MS
Doxorubicin is a highly effective and widely used cytotoxic agent with application that is limited by cardiotoxicity related to the cumulative dose of the drug. A large-scale study that retrospectively evaluated the cardiotoxicity of doxorubicin reported that an estimated 7% of patients developed doxorubicin-related congestive heart failure (CHF) after a cumulative dose of 550 mg/m2. To assess whether this estimate is reflective of the incidence in the broader clinical oncology setting, the authors evaluated data from three prospective studies to determine both the incidence of doxorubicin-related CHF and the accumulated dose of doxorubicin at which CHF occurs.
METHODSA group of 630 patients who were randomized to a doxorubicin-plus-placebo arm of three Phase III studies, two studies in patients with breast carcinoma and one study in patients with small cell lung carcinoma, were included in the analysis.
Referred From: https://onlinelibrary.wiley.com/doi/10.1002/cncr.11407
Author(s): Long ZJ, Hu Y, Li XD, He Y, Xiao RZ, et al.
Author(s): Lipshultz SE, Sambatakos P, Maguire M, Karnik R, Ross SW, et al.
Author(s): Suzumiya J, Ohshima K, Tamura K, Karube K, Uike N, et al.
Author(s): Dalen VEC, Raphael MF, Caron HN, Kremer LC
Author(s): Kobayashi S, Volden P, Timm D, Mao K, Xu X, et al.
Author(s): Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, et al.
Author(s): Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, et al.
Author(s): Cario G, Rhein P, Mitlohner R, Zimmermann M, Bandapalli OR, et al.
Author(s): Aiken MJ, Suhag V, Garcia CA, Acio E, Moreau S, et al.
Author(s): Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE
Author(s): Yeh ET, Bickford CL
Author(s): Lebrecht D, Setzer B, Ketelsen UP, Haberstroh J, Walker UA
Author(s): Vandecruys E, Mondelaers V, De Wolf D, Benoit Y, Suys B
Author(s): Barge-Caballero E, Segovia-Cubero J, Almenar-Bonet L, Gonzalez-Vilchez F, Villa-Arranz A, et al.
Author(s): Schweiger M, Dave H, Lemme F, Cavigelli-Brunner A, Romanchenko O, et al.
Author(s): Kurihara C, Nishimura T, Nawata K, Kinoshita O, Hisagi M, et al.
Author(s): Lipshultz SE, Franco VI, Cochran TR
Author(s): Orgel E, Zung L, Ji L, Finklestein J, Feusner J, et al.
Author(s): Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, et al.
Author(s): Palazzuoli A, Gallotta M, Quatrini I, Nuti R
Author(s): Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, et al.
Author(s): Armenian SH, Hudson MM, Mulder RL, Chen MH, Constine LS, et al.
Author(s): Harake D, Franco VI, Henkel JM, Miller TL, Lipshultz SE
Author(s): Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, et al.
Author(s): Feuerstein GZ, Ruffolo RR
Author(s): Arozal W, Sari FR, Watanabe K, Arumugam S, Veeraveedu PT, et al.
Author(s): Goldberg JM, Scully RE, Sallan SE, Lipshultz SE
Author(s): Thompson PA, Rosner GL, Matthay KK, Moore TB, Bomgaars LR, et al.
